I would like to personally invite you to attend the 2017 ISPE/FDA/PQRI Quality Manufacturing Conference, jointly sponsored by and organized with the FDA. If you have been to one of the previous Quality Manufacturing Conferences, you have an idea of the value of this opportunity. If you have never been to this conference before you will immediately see how important and relevant this is to your area of expertise in the manufacturing life cycle. This year promises to meet and exceed your expectations by emphasizing the top priorities from CDERs Office of Pharmaceutical Quality (OPQ) and Office of Compliance and the Office of Global Regulatory Policy and Operations. Highlights of the conference include:
And that is just the tip of the iceberg! Additional highlights include:
Calling all Young Professionals, Senior Leaders, Development, Quality, Engineering, Facility, and Manufacturing Professionals, and everyone involved in the life cycle of manufacturing medicines for patient needs today and in the future, you need to attend! I hope to see you there!
P.S. Don’t miss the Data Integrity Workshop on June 4th, immediately before the 2017 ISPE/FDA/PQLI Quality Manufacturing Conference, with FDA Compliance, Pharmaceutical Industry Compliance and ISPE GAMP® experts, facilitating an interactive workshop on successfully implementing a robust data integrity program avoiding compliance issues. Sign up now: www.ISPE.org/2017-Data-Integrity-Workshop/Register
The following blog post was provided by Peyton Myers, an undergraduate student at Appalachian State University. Myers attended the 2023 ISPE Annual Meeting & Expo in Las Vegas as an ISPE Foundation Professional Development Grant recipient.
The integration of data science in biopharmaceutical manufacturing, emphasizing data quality, tech transfer efficiency, and process optimization, is the heart of this track. Led by industry experts, discussions explore leveraging digital twins, predictive analytics, and continuous improvement initiatives. Additionally, interactive roundtable discussions provide attendees with a dynamic forum...
The pharmaceutical sector stands at a crossroads of immense possibilities. We are witnessing an unprecedented surge in innovation, fueled by a remarkable partnership between industry and regulatory authorities. For example, there are initiatives fostered by the US Food and Drug Administration (US FDA) to promote innovation with programs such as CATT (CBER Advanced Technologies Team) and ETP...